Since the TFR is found to be upregulated on the surface of various cancer cells including breast cancer, lung adenocarcinoma, glioma, and chronic lymphocytic leukemia, it became an attractive molecule for cancer therapeutics [98,99,100,101,102]. This evidence concerns the gene TFRC and B-cell chronic lymphocytic leukemia.